Samuel M Jenness1, Steven M Goodreau2, Eli Rosenberg1, Emily N Beylerian3, Karen W Hoover4, Dawn K Smith4, Patrick Sullivan1,5. 1. Department of Epidemiology. 2. Department of Anthropology. 3. Center for Studies in Demography and Ecology, University of Washington, Seattle. 4. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. 5. Department of Global Health, Emory University.
Abstract
BACKGROUND: Preexposure prophylaxis (PrEP) is effective for preventing human immunodeficiency virus (HIV) infection among men who have sex with men (MSM) within trial settings. Population impact will depend on clinical indications for PrEP initiation, coverage levels, and drug adherence. No modeling studies have estimated the impact of clinical practice guidelines for PrEP issued by the Centers for Disease Control and Prevention (CDC). METHODS: Mathematical models of HIV transmission among MSM were used to estimate the percentage of infections averted (PIA) and the number needed to treat (NNT) under behavioral indications of the CDC's PrEP guidelines. We modeled the contribution of these indications while varying treatment coverage and adherence. RESULTS: At 40% coverage of indicated MSM over the next decade, application of CDC guidelines would avert 1162 infections per 100 000 person-years, 33.0% of expected infections. The predicted NNT for the guidelines would be 25. Increasing coverage and adherence jointly raise the PIA, but reductions to the NNT were associated with better adherence only. CONCLUSIONS: Implementation of CDC PrEP guidelines would result in strong and sustained reductions in HIV incidence among MSM in the United States. The guidelines strike a good balance between epidemiological impact (PIA) and efficiency (NNT) at plausible scale-up levels. Adherence counseling could maximize public health investment in PrEP by decreasing the NNT.
BACKGROUND: Preexposure prophylaxis (PrEP) is effective for preventing human immunodeficiency virus (HIV) infection among men who have sex with men (MSM) within trial settings. Population impact will depend on clinical indications for PrEP initiation, coverage levels, and drug adherence. No modeling studies have estimated the impact of clinical practice guidelines for PrEP issued by the Centers for Disease Control and Prevention (CDC). METHODS: Mathematical models of HIV transmission among MSM were used to estimate the percentage of infections averted (PIA) and the number needed to treat (NNT) under behavioral indications of the CDC's PrEP guidelines. We modeled the contribution of these indications while varying treatment coverage and adherence. RESULTS: At 40% coverage of indicated MSM over the next decade, application of CDC guidelines would avert 1162 infections per 100 000 person-years, 33.0% of expected infections. The predicted NNT for the guidelines would be 25. Increasing coverage and adherence jointly raise the PIA, but reductions to the NNT were associated with better adherence only. CONCLUSIONS: Implementation of CDC PrEP guidelines would result in strong and sustained reductions in HIV incidence among MSM in the United States. The guidelines strike a good balance between epidemiological impact (PIA) and efficiency (NNT) at plausible scale-up levels. Adherence counseling could maximize public health investment in PrEP by decreasing the NNT.
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Susan P Buchbinder; David V Glidden; Albert Y Liu; Vanessa McMahan; Juan V Guanira; Kenneth H Mayer; Pedro Goicochea; Robert M Grant Journal: Lancet Infect Dis Date: 2014-03-07 Impact factor: 25.071
Authors: D R Holtgrave; N L Qualls; J W Curran; R O Valdiserri; M E Guinan; W C Parra Journal: Public Health Rep Date: 1995 Mar-Apr Impact factor: 2.792
Authors: Jason Kessler; Julie E Myers; Kimberly A Nucifora; Nana Mensah; Christopher Toohey; Amin Khademi; Blayne Cutler; Scott Braithwaite Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Estelle Ouellet; Madeleine Durand; Jason R Guertin; Jacques LeLorier; Cécile L Tremblay Journal: Can J Infect Dis Med Microbiol Date: 2015 Jan-Feb Impact factor: 2.471
Authors: Steven M Goodreau; Nicole B Carnegie; Eric Vittinghoff; Javier R Lama; Jorge Sanchez; Beatriz Grinsztejn; Beryl A Koblin; Kenneth H Mayer; Susan P Buchbinder Journal: PLoS One Date: 2012-11-29 Impact factor: 3.240
Authors: Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill Journal: Lancet Date: 2015-09-09 Impact factor: 79.321
Authors: Kenneth H Mayer; Philip A Chan; Rupa R Patel; Charlene A Flash; Douglas S Krakower Journal: J Acquir Immune Defic Syndr Date: 2018-02-01 Impact factor: 3.731
Authors: Aaron J Siegler; Anna Bratcher; Kevin M Weiss; Farah Mouhanna; Lauren Ahlschlager; Patrick S Sullivan Journal: Ann Epidemiol Date: 2018-05-26 Impact factor: 3.797
Authors: Charlotte-Paige Rolle; Eli S Rosenberg; Aaron J Siegler; Travis H Sanchez; Nicole Luisi; Kevin Weiss; Scott Cutro; Carlos Del Rio; Patrick S Sullivan; Colleen F Kelley Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Patrick S Sullivan; Robertino Mera Giler; Farah Mouhanna; Elizabeth S Pembleton; Jodie L Guest; Jeb Jones; Amanda D Castel; Howa Yeung; Michael Kramer; Scott McCallister; Aaron J Siegler Journal: Ann Epidemiol Date: 2018-06-22 Impact factor: 3.797
Authors: Erika G Martin; Roderick H MacDonald; Daniel E Gordon; Carol-Ann Swain; Travis O'Donnell; John Helmeset; Adenantera Dwicaksono; James M Tesoriero Journal: Public Health Rep Date: 2020 Jul/Aug Impact factor: 2.792
Authors: Steven M Goodreau; Eli S Rosenberg; Samuel M Jenness; Nicole Luisi; Sarah E Stansfield; Gregorio A Millett; Patrick S Sullivan Journal: Lancet HIV Date: 2017-04-18 Impact factor: 12.767
Authors: Brandon D L Marshall; William C Goedel; Maximilian R F King; Alyson Singleton; David P Durham; Philip A Chan; Jeffrey P Townsend; Alison P Galvani Journal: Lancet HIV Date: 2018-06-13 Impact factor: 12.767
Authors: Helen L Zhang; Sarah K Rhea; Christopher B Hurt; Victoria L Mobley; Heidi Swygard; Arlene C Seña; Mehri S McKellar Journal: J Acquir Immune Defic Syndr Date: 2018-01-01 Impact factor: 3.731